NEOSENT: Early Anti-PD-1 Therapy In High-Risk Stage II Melanoma
Recruiting · NCT07680699 · Observational (researchers observe without assigning treatment) · Lead sponsor: AC Camargo Cancer Center
View the official record on ClinicalTrials.gov →Interventions studied
Anti-PD1 Therapy Timing
What this trial is about
This is an observational cohort study evaluating clinical and pathological outcomes in patients with high-risk stage II melanoma. Patients are included after receiving treatment as part of routine clinical practice. Decisions about treatment, including whether to start anti-PD1 therapy before surgery, are made by the treating physician and are not influenced by the study. The study compares outcomes between patients who started anti-PD1 therapy before surgery and those treated according to the usual timing in clinical practice. No treatments are assigned as part of the study.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- \- Adults (≥18 years) with histologically confirmed cutaneous melanoma stage IIB or IIC or stage III (N1c), managed in routine clinical practice.
Exclusion criteria
- Patients without sufficient clinical or follow-up data.
- Patients who do not provide informed consent (for prospective cohort).
Where it is running
1 location listed.
- AC Camargo Cancer Center - São Paulo, São Paulo, Brazil